Navigation Links
New Drug Promising Against Rheumatoid Arthritis
Date:6/29/2009

Golimumab might help where similar drugs failed, research finds

MONDAY, June 29 (HealthDay News) -- The immunosuppressive drug golimumab shows promise in treating rheumatoid arthritis patients who don't respond to other drugs, according to a new study. Golimumab is from the family of drugs called tumor necrosis factor-a (TNF-a) inhibitors.

The new study included 461 patients in 10 countries who were randomly selected to receive either injections of placebo, 50 milligrams of golimumab or 100 milligrams of golimumab. The injections were given every four weeks for 24 weeks.

After 14 weeks, 35 percent of patients taking 50 milligrams of golimumab and 38 percent of those taking 100 milligrams of the drug achieved a 20 percent or higher improvement in American College of Rheumatology criteria for assessment of rheumatoid arthritis (ACR 20), compared with 18 percent of patients taking the placebo.

The study also found that among the 58 percent of patients who had discontinued a previous TNF-a inhibitor treatment because it wasn't effective, ACR 20 was achieved by 36 percent of patients taking 50 milligrams of golimumab, 43 percent of those taking 100 milligrams of golimumab and 18 percent of those in the placebo group.

After 24 weeks of treatment, serious adverse events were recorded in five percent of patients taking 50 milligrams of golimumab, four percent of those taking 100 milligrams of the drug and in 10 percent of patients on placebo.

"Golimumab reduces the signs and symptoms of active rheumatoid arthritis and improves physical function in patients who had previously received TNF-a inhibitors, which suggests that switching patients from one TNF-a inhibitor to golimumab is effective and generally well-tolerated," wrote Josef Smolen of the Medical University of Vienna and Hietzing Hospital in Vienna, Austria, and colleagues.

In a commentary, Dr. Yusuf Yazici of New York University Hospital for Joint Diseases, New York City, said that "for those patients who have failed or had an inadequate response to etanercept, infliximab, adalimumab or abatacept, golimumab might be a good option."

The study, which was funded by drug makers Centocor, Inc. and Schering- Plough, appears online June 29 inThe Lancet.

Rheumatoid arthritis is a chronic inflammatory disease that affects about 1.3 million people in the United States. TNF-a inhibitors are widely used to treat the disease, but 30 to 50 percent of patients treated with these drugs are intolerant or have an inadequate response to the drugs. Prior to this study, no controlled trials had examined whether patients who don't respond to one TNF-a inhibitor might respond to another.

More information

The Arthritis Foundation has more about rheumatoid arthritis.



-- Robert Preidt



SOURCE: The Lancet, news release, June 28, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Respiratory Rally a Promising Practice in the Fight Against Chronic Disease
2. Promising Therapy for Prostate Cancer
3. Promising biomarker and candidate tumor suppressor gene identified for colorectal cancer
4. AGH Joins Select Group of Medical Centers in Study of Promising New Technology for Treatment of Heart Failure
5. 17 of Americas Most Promising Scientists Selected as 2009 Pew Scholars in the Biomedical Sciences
6. CORRECTION: Viral Genetics Pursues Promising New Therapy for Lyme Disease With Grant from Time for Lyme, Inc.
7. Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer
8. Triple drug combination is promising option to treat metastatic HER2+ breast cancer
9. Aleres Dr. Gordon Norman Highlights Challenges and Promising Solutions to U.S. Healthcare System to International Health Insurance Executives
10. New drug shows promising results for psoriatic arthritis
11. Will Obamas Stem Cell Announcement Doom Promising Adult Stem Cell Research?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug Promising Against Rheumatoid Arthritis
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. ... recently contributed a medical article to the newly revamped Cosmetic Town journal ... spotlights the hair transplant procedure known as Follicular Unit Extraction (FUE). ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical , ... company with their  2017 New Product Innovation Award for ... extensive primary and secondary medical device market research by Frost ... its first-to-market OTC, drug-free pain relief product, the AVACEN 100, ... to treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... EXTON, Pa. , Oct. 12, 2017 ... global leader in innovative solutions for injectable drug administration, ... results before the market opens on Thursday, October 26, ... discuss the results and business expectations at 9:00 a.m. ... 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
Breaking Medicine Technology: